My site

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera

NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures

... Read more »

(BUSINESS WIRE) -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Company was not in compliance with Nasdaq’s Listing Rule 5250(c)(2) since the Company did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025.

As previously disclosed, the Company received a delisting determination letter (the “Staff Determination”) from Nasdaq in November 2025. The Company requested a hearing before the Nasdaq Hearings Panel to appeal the Staff Determination on November 19, 2025. Nasdaq has informed the Company that the Nasdaq Hearings Panel will also consider the matter addressed in the Notification Letter at a hearing scheduled for January 8, 2026 at which the Compan ... Read more »

(BUSINESS WIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here.

Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and most sophisticated platforms across a wide range of medical disciplines, continuously integrating this knowle ... Read more »

Abu Dhabi, United Arab Emirates - Monday, 05. January 2026


Based on new hybrid-architecture, models deliver higher accuracy while running on smaller parameter sizes

Launch underscores UAE push to compete with global AI leaders in high-performance language models



The Technology Innovation Institute (TII), the applied research arm of Abu Dhabi’s Advanced Technology Research Council (ATRC), has announced Falcon-H1 Arabic, a newly developed large language model built on a hybrid Mamba-Transformer architecture. Representing a complete departure from previous transformer-based versions, this new model establishes itself as the highest-performing system on the Open Arabic LLM Leaderboard (OALL).

This milestone sets Falcon-H1 Arabic as the leading Arabic AI model currently available, outperforming models several times larger while delivering state-of-the-art accuracy, context handling, and linguistic representation.

His Excellency Faisal al Ba ... Read more »

BEIJING - Monday, 05. January 2026

(BUSINESS WIRE) -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order governing the Company’s board composition and corporate actions pending trial, and announced the engagement of Zhonghua Certified Public Accountants LLP (“Zhonghua”), an affiliate of the global accounting network UHY International, as the Company’s independent auditor and registered public accounting firm.

Update on Antigua High Court Order

Further to the order issued by the Antigua High Court (the “Court”) previously disclosed by the Company in a press release dated December 17, 2025, the Court has updated its order to provide that directors Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Dr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Weidong Yin (collective ... Read more »

LAS VEGAS - Monday, 05. January 2026 AETOSWire Print



(BUSINESS WIRE)--Quectel Wireless Solutions, an end-to-end global IoT solutions provider, announced the official launch of its new-generation flagship smart module, the SP895BD-AP. Powered by the Qualcomm Dragonwing™ Q-8750 processor, the SP895BD-AP module boasts enhanced graphics processing capabilities, superior visual imaging effects, and advanced edge computing performance, meeting the requirements of high-end devices such as video conferencing systems, ultra-high-definition (UHD) displays, image synthesis equipment, computing power boards, smart retail terminals and smart home appliances.

The SP895BD-AP redefines performance boundaries with its advanced hardware architecture. Powered by the Dragonwing Q-8750 processor built on a 3nm process, it features an 8-core high-performance Oryon™ CPU with a maximum frequency of 2×4.32 GHz + 6×3.53 GHz. Compared with the previous-generation (Series 8) chi ... Read more »

YONGIN, South Korea - Monday, 05. January 2026 AETOSWire

Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT Technology
World's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell Therapies
Drastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations


(BUSINESS WIRE)--Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated C ... Read more »

• Falcon H1R 7B Packs Advanced Reasoning into a Compact 7 Billion Parameter Model Optimized for Speed and Efficiency
• TII’s Latest AI Model Outperforms Larger Rivals from Microsoft, Alibaba, and NVIDIA on Key Benchmarks

The Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has announced the release of Falcon H1R 7B, a next-generation AI model that takes a significant step toward making advanced AI more accessible than ever, by delivering world-class reasoning performance in a compact, efficient, and openly available format.

With just 7 billion parameters, Falcon H1R 7B challenges and, in many cases, outperforms larger open-source AI models from around the world, including models from Microsoft (Phi 4 Reasoning Plus 14B), Alibaba (Qwen3 32B), and NVIDIA (Nemotron H 47B). This model release reaffirms TII’s position at the forefront of efficient AI innovation and reinforces the UAE’s growing ... Read more »